HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $9.00 target price on the stock.
Alpha Tau Medical Stock Performance
Shares of NASDAQ DRTS opened at $2.53 on Wednesday. The stock has a market cap of $176.27 million, a price-to-earnings ratio of -6.17 and a beta of 0.75. The company has a 50 day simple moving average of $2.46 and a two-hundred day simple moving average of $2.81. The company has a current ratio of 11.60, a quick ratio of 11.60 and a debt-to-equity ratio of 0.07. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $4.37.
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last announced its quarterly earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. As a group, analysts predict that Alpha Tau Medical will post -0.5 earnings per share for the current year.
Institutional Trading of Alpha Tau Medical
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
- Five stocks we like better than Alpha Tau Medical
- How to invest in marijuana stocks in 7 steps
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 6/24 – 6/28
- Options Trading – Understanding Strike Price
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.